Claims

We claim:

1. Use of a botulinum neurotoxin in the manufacture of a medicament for prophylactically treating a headache in a patient with chronic migraine headaches, wherein the medicament is to be administered locally to the frontalis, corrugator, procereus, occipitalis, temporalis, trapezius and cervical paraspinal muscles of the patient that suffers from the migraine headache;

wherein the botulinum neurotoxin is to be administered, to the frontalis at about twenty units divided among four sites of injection; to the corrugator at about ten units divided among two sites of injection; to the procerus at about five units to one site of injection; to the occipitalis at about thirty units divided among six sites of injection to about forty units divided among eight sites of injection; to the temporalis at about forty units divided among eight sites of injection up to fifty units divided among ten sites of injection; to the trapezius at about thirty units divided among six sites of injection up to about fifty units divided among ten sites of injection and to the cervical paraspinal muscles at about twenty units divided among four sites of injection;

wherein the botulinum neurotoxin is to be injected at 31 to 39 injection sites.

2. The use of claim 1 wherein the total amount of botulinum neurotoxin administered is from about 155 units to about 195 units of onabotulinumtoxinA.

~~3. The use of claim 1 wherein the botulinum neurotoxin is type B.~~

~~4. The use of claim 1 wherein the botulinum neurotoxin is type E.~~

~~5~~3. The use of claim 1 wherein the botulinum neurotoxin is type A.